The home infusion industry is experiencing significant growth due to the increasing number of aging patients wanting to ...

Tocilizumab treatments in patients with noninfectious uveitis demonstrated high rates of success at 1 year follow ups.

A recent shortage of intravenous solutions underscores the need to address the fragile supply chain for infusion therapy ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

The Quadruple Aim—a framework originally rooted in improving patient experience, enhancing population health, and achieving ...

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its ...

GRCE READ THE FULL GRCE RESEARCH REPORT We are initiating coverage of Grace Therapeutics, Inc. (NASDAQ:GRCE) with a valuation of $12.50 per share. This value is based on our estimates for the successf ...

IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named one of Fortune’s 100 Fastest Growing Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance ...

Principal treatment-related toxicities that come from amivantamab administration include skin-related reactions, higher risk of venous thrombolism, and infusion-related reactions.

Get the facts on cost and allopurinol, how generics compare with brand names, what financial assistance may be available, and ...

Becton, Dickinson and Company BDX, popularly known as BD, recently launched the new BD Intraosseous (IO) Vascular Access ...

Despite disruption to its supply chain, Option Care Health’s quick and “aggressive” response allowed the provider to continue ...